Tony Huge

Tony Huge Field Report — April 2026: Vision Protocol

Table of Contents

Better Than Natural — Quarterly Field Report

Vision Protocol

April 2026 — Edition #002

Reversing age-related vision decline. Peptides, supplements, and training protocols.

OPENING: WHY THIS REPORT EXISTS

Vision is the cognitive sense most people take for granted until it starts degrading — and by the time they notice, the decline has been compounding for years. The standard medical response is corrective lenses, laser surgery, or waiting until cataracts develop enough to justify replacement. None of these address the underlying biology. None of them reverse anything.

This report applies the Better Than Natural framework — the same Six Laws of Biochemistry Physics that govern every protocol Tony runs — to the specific problem of age-related vision decline. The premise is the same as every other BTN report: the body you were born with is the starting point, not the ceiling. Your eyes are biological systems running on chemistry. Chemistry can be optimized.

The underground is ahead of the clinical literature on this, just as it is on nootropics, peptides, and performance optimization. Compounds that mainstream ophthalmology won’t discuss for another five to ten years are being run now by self-experimenters who understand the mechanisms and are willing to act on incomplete but directionally correct data.

This report covers all of it — the clinical foundation and the frontier protocols — evaluated through the same Laws that govern every BTN recommendation.

WHY VISION DEGRADES: THE FOUR MECHANISMS

Before you can reverse vision decline, you need to understand what’s actually happening at the cellular level. Most people think vision loss is just “aging.” It’s not. It’s four specific, addressable biological mechanisms operating simultaneously.

Mechanism 1: Oxidative Damage to the Retina

The retina is one of the most metabolically active tissues in the human body. It consumes oxygen at a rate that rivals the brain. High metabolic activity means high production of reactive oxygen species (ROS). Over decades, cumulative oxidative damage degrades the photoreceptor cells and the retinal pigment epithelium (RPE) — the support layer that keeps photoreceptors functional.

This is the primary driver of age-related macular degeneration (AMD). The macula — the center of your visual field where detail resolution lives — takes the heaviest oxidative hit because it has the highest concentration of photoreceptors and therefore the highest metabolic demand.

Blue light exposure from screens accelerates this. Not because blue light is uniquely dangerous in isolation, but because it increases ROS production in retinal tissue that’s already under oxidative load. The cumulative effect over years of screen exposure on top of baseline metabolic ROS is significant.

Mechanism 2: Mitochondrial Dysfunction in Retinal Cells

Retinal cells are mitochondria-dense. When mitochondrial function declines — as it does with age across all tissues — retinal cells lose the energy production capacity needed to maintain photoreceptor health, clear metabolic waste, and support the visual cycle (the chemical process that converts light into neural signals).

This is where the NAD+ decline becomes directly relevant to vision. The same age-related NAD+ depletion that affects cognitive function affects retinal mitochondria. Compounds that support mitochondrial function and NAD+ levels are not just nootropics — they are vision-protective.

Mechanism 3: Lens Protein Aggregation (Presbyopia and Cataracts)

The lens of the eye is made of crystallin proteins that must remain transparent and flexible. Over time, these proteins undergo glycation, oxidation, and cross-linking — they literally stiffen and cloud. Presbyopia (the inability to focus on close objects that hits most people in their 40s) is the flexibility problem. Cataracts are the transparency problem. Same underlying mechanism at different stages.

The conventional response to presbyopia is reading glasses. The conventional response to cataracts is surgical lens replacement. Neither addresses the protein aggregation mechanism. Compounds that reduce glycation, support protein turnover, and provide targeted antioxidant protection to the lens offer a mechanistic approach that corrective optics don’t.

Mechanism 4: Ciliary Muscle Atrophy

The ciliary muscle controls lens shape for focusing at different distances. Like any muscle, it atrophies with disuse. Modern screen-dominant lifestyles keep the ciliary muscle locked in near-focus position for hours daily. The muscle loses its range of motion. This accelerates presbyopia independently of lens protein changes.

This is the one mechanism that has a purely physical intervention: ciliary muscle training. No compounds required. But almost nobody does it, because almost nobody understands that accommodation (the eye’s focusing mechanism) is a trainable physical function.

THE MIRACLE MOLECULE STACK FOR VISION

Peptides and compounds with direct mechanisms of action on retinal health, lens protection, and ocular tissue repair

Epitalon (Epithalon) — Telomerase Activation in Retinal Cells

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide Epithalamin, originally researched by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism is telomerase activation — specifically, it increases telomerase activity in human somatic cells, which directly addresses the cellular aging mechanism in retinal tissue.

The relevance to vision: retinal pigment epithelium (RPE) cells are among the first to show telomere shortening with age. When RPE cells senesce, they lose the ability to support photoreceptors — the cells that actually detect light. Epitalon’s telomerase activation in these cells is not a theoretical benefit. Russian clinical data spanning decades shows measurable improvements in retinal function in aging populations.

The underground has been running Epitalon for retinal health specifically for approximately eight years. Consistent reports: improved contrast sensitivity, reduced floaters over time, and subjective improvements in low-light vision. These align precisely with the mechanism — healthier RPE cells supporting better photoreceptor function.

Protocol: 10mg subcutaneous injection daily for 10-20 days, cycled 2-3 times per year. This is the standard Khavinson protocol adapted by the biohacking community.

SS-31 (Elamipretide) — Mitochondrial Rescue for Retinal Cells

SS-31 is a mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane, specifically binding to cardiolipin — a phospholipid essential for electron transport chain function. It stabilizes mitochondrial cristae structure and reduces ROS production at the source.

For vision specifically: SS-31 has clinical trial data (Phase II) for dry AMD showing stabilization and modest improvement in retinal function. The mechanism is direct — retinal cells are mitochondria-dense, and restoring mitochondrial efficiency in these cells directly addresses Mechanism 2 (mitochondrial dysfunction).

This is one of the few peptides with actual ophthalmology clinical data. The underground lead time on this one is approximately five years — biohackers were running it for retinal support before the AMD trials published.

Protocol: 5mg subcutaneous daily for 4-6 weeks, then maintenance at 2-3x weekly. Some protocols use 40mg weekly as an alternative.

BPC-157 — Systemic Tissue Repair Including Ocular

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice with broad tissue-repair properties. Its mechanism includes upregulation of growth hormone receptors, promotion of angiogenesis in damaged tissue, and modulation of the nitric oxide system.

For vision: BPC-157’s tissue repair properties extend to ocular tissue. Preclinical data shows accelerated corneal healing and retinal tissue repair. The underground reports consistent improvements in dry eye symptoms and recovery from eye strain — mechanistically consistent with BPC-157’s known tissue-repair and anti-inflammatory properties.

BPC-157 is not a vision-specific compound. It’s a systemic repair compound that happens to benefit ocular tissue as part of its broad mechanism. Law 3 — synergy — means including it in a vision protocol adds tissue repair capacity that the vision-specific compounds don’t duplicate.

Protocol: 250-500mcg subcutaneous daily, or 500mcg BID for acute eye recovery. Oral BPC-157 (stable form) at 500mcg daily is an alternative for those avoiding injections.

GHK-Cu — Tissue Remodeling and Anti-Inflammatory

GHK-Cu (copper peptide) is a naturally occurring tripeptide with copper that declines significantly with age. It activates genes involved in tissue remodeling, reduces inflammation, and promotes stem cell activity. Over 4,000 genes are influenced by GHK-Cu — more than any other single peptide studied.

For vision: GHK-Cu’s anti-inflammatory and tissue remodeling properties address the chronic low-grade inflammation that contributes to AMD progression and general retinal degradation. Its promotion of collagen synthesis supports the structural integrity of ocular tissues including the sclera and cornea.

Protocol: 200mcg subcutaneous daily, or topical application around the orbital area. Some protocols combine with microneedling for periorbital delivery.

NAD+ Support (5-Amino-1MQ) — Mitochondrial Energy for Retinal Cells

As covered in the Nootropics Field Report, 5-Amino-1MQ inhibits NNMT to elevate intracellular NAD+ more efficiently than precursor loading (NMN/NR). The vision application is direct: retinal cells are among the most energy-demanding cells in the body. NAD+ decline with age directly impairs their function.

A 2023 study demonstrated that NAD+ supplementation protected retinal ganglion cells from degeneration in glaucoma models. The mechanism: restored mitochondrial function in cells under metabolic stress. 5-Amino-1MQ achieves higher intracellular NAD+ than NMN/NR, making it the preferred approach for retinal mitochondrial support.

Protocol: Standard 5-Amino-1MQ dosing as per the Nootropics Field Report protocol. The vision benefit is systemic — no separate dosing needed.

MOTS-C — Mitochondrial-Derived Peptide

MOTS-C is a mitochondrial-derived peptide encoded in the mitochondrial genome. It regulates metabolic homeostasis, reduces oxidative stress, and has direct effects on cellular energy production. Unlike peptides that target mitochondria externally (like SS-31), MOTS-C is part of the mitochondrial communication system itself.

For vision: MOTS-C’s metabolic regulation and oxidative stress reduction complement SS-31’s direct mitochondrial stabilization. Together they address Mechanism 2 from two angles — SS-31 stabilizes mitochondrial structure while MOTS-C improves mitochondrial signaling and metabolic function. This is a textbook application of the Tony Huge Laws of Biochemistry Physics — using complementary mechanisms to target a single system from multiple angles for a synergistic effect.

Protocol: 5-10mg subcutaneous, 3x weekly. Often cycled with SS-31 for comprehensive mitochondrial support.

THE TONY HUGE VISION PROTOCOL — APRIL 2026

Three-tier architecture following the same beginner-to-advanced progression as every BTN protocol. Start at Tier 1. Add Tier 2 after 60 days of consistent Tier 1. Tier 3 is for experienced biohackers only.

Tier 1: Foundation — OTC Supplements (~$40-60/month)

Evidence-based, widely available, zero prescription required. This tier alone outperforms doing nothing by a significant margin.

  • Lutein 20mg + Zeaxanthin 4mg daily — Macular pigment carotenoids. These concentrate in the macula and act as a natural blue-light filter and antioxidant shield. The AREDS2 formulation validated this. Take with fat for absorption.
  • Astaxanthin 12mg daily — The most potent carotenoid antioxidant. Crosses the blood-retinal barrier (most antioxidants don’t). Reduces eye fatigue, improves accommodation, and protects against UV-induced retinal damage. Take with fat.
  • Omega-3 (DHA-dominant) 2-3g daily — DHA is a structural component of retinal cell membranes. Deficiency directly impairs photoreceptor function. The retina has the highest DHA concentration of any tissue in the body.
  • Vitamin A (retinol) 5,000 IU daily — Direct precursor to retinal (11-cis-retinal), the chromophore that enables photoreceptors to detect light. Without adequate retinal, the visual cycle literally cannot complete.
  • Bilberry extract 320mg daily (standardized to 25% anthocyanins) — Improves retinal microcirculation and provides targeted antioxidant protection. The World War II RAF pilot story about bilberry and night vision has a real mechanistic basis.
  • Magnesium L-Threonate 2000mg before sleep — Already in the Nootropics protocol. Supports intraocular pressure regulation and retinal nerve function.
  • NAC (N-Acetylcysteine) 600mg daily — Glutathione precursor. The lens depends on glutathione for maintaining protein transparency. NAC supports lens glutathione levels, directly addressing Mechanism 3.

Tier 2: Intermediate — Peptide Integration

Adds targeted peptide interventions to the foundation. Requires comfortable with subcutaneous injection and sourcing research peptides.

  • Epitalon — 10mg SC daily x 20 days, 2-3 cycles per year. RPE telomerase activation for retinal cell longevity.
  • BPC-157 — 250mcg SC daily (or 500mcg oral stable form). Systemic tissue repair extending to ocular tissue.
  • 5-Amino-1MQ — Standard dosing per Nootropics protocol. NAD+ elevation for retinal mitochondrial support.
  • GHK-Cu — 200mcg SC daily. Tissue remodeling and anti-inflammatory support for ocular structures.

Tier 3: Advanced — Full Mitochondrial Rescue

The complete protocol for serious age-related vision decline or aggressive preventive optimization. Experienced biohackers only.

  • SS-31 (Elamipretide) — 5mg SC daily x 4-6 weeks, then 2-3x weekly maintenance. Direct mitochondrial rescue for retinal cells.
  • MOTS-C — 5-10mg SC 3x weekly. Mitochondrial signaling and metabolic regulation. Complementary mechanism to SS-31.
  • Epitalon + BPC-157 + GHK-Cu — Full Tier 2 peptide stack running concurrently.
  • All Tier 1 supplements — Non-negotiable foundation.

Law 5 applies rigorously: When running this many compounds concurrently, side effect aggregation must be monitored. Blood work at baseline, 30 days, and 90 days. Intraocular pressure monitoring recommended.

VISION TRAINING: CILIARY MUSCLE REHABILITATION

This section requires zero compounds, zero money, and addresses Mechanism 4 (ciliary muscle atrophy) directly. Most people’s eyes are locked in near-focus for 8-14 hours daily. The ciliary muscle atrophies exactly the way any muscle does when held in one position indefinitely.

The Daily Protocol (10 minutes total)

Exercise 1: Near-Far Focus Shifting (3 minutes)

Hold your thumb 6 inches from your face. Focus on the thumbprint detail until it’s sharp. Then shift focus to an object at least 20 feet away. Hold focus on the distant object for 5 seconds. Return to thumb. Repeat for 3 minutes. This is the basic range-of-motion exercise for the ciliary muscle — extending and contracting through its full range.

Exercise 2: The 20-20-20 Rule — Enhanced Version (throughout the day)

Every 20 minutes of screen work, look at something 20+ feet away for 20 seconds. The standard recommendation. The enhanced version: during those 20 seconds, actively focus on fine detail at distance — read a sign, count leaves on a tree, identify a bird. Active focusing at distance engages the ciliary muscle more than passive gazing.

Exercise 3: Accommodation Resistance Training (3 minutes)

Slowly move a pen from arm’s length toward your nose, maintaining focus on the tip. When focus breaks (the point of accommodation failure), hold at that distance for 5 seconds, then slowly move it back out. Repeat. This is progressive overload for the ciliary muscle — you’re training it at its failure point, the same principle that drives adaptation in any muscle.

Exercise 4: Peripheral Vision Activation (2 minutes)

Fix your gaze on a central point. Without moving your eyes, become aware of objects at the extreme edges of your visual field — top, bottom, left, right. Hold awareness at each edge for 15 seconds. This activates the rod photoreceptors in the peripheral retina that modern screen-focused life chronically underutilizes.

Exercise 5: Palming Recovery (2 minutes)

Cup your palms over your closed eyes, blocking all light. Rest. Breathe. This isn’t mystical — complete darkness allows the photoreceptors to fully regenerate rhodopsin (the visual pigment consumed during light exposure). Two minutes of complete darkness resets the visual cycle more effectively than simply closing your eyes in a lit room.

WHAT ACCELERATES VISION DECLINE — RANKED BY IMPACT

These are the environmental and behavioral factors that accelerate the four mechanisms. Ranked by actual impact based on the literature and underground observation, not by what gets the most media attention.

1. Chronic Unmanaged Blood Sugar (HIGHEST IMPACT)

Glycation damages lens proteins (Mechanism 3) and retinal blood vessels faster than any other single factor. Diabetic retinopathy is the extreme manifestation, but sub-clinical glycation accelerates lens clouding and macular damage in anyone running chronically elevated glucose — even within “normal” ranges. This is the number one accelerant by a wide margin. If you’re running a vision protocol while eating high-glycemic meals three times daily, you’re fighting the protocol with your fork.

2. Sustained Near-Focus Without Breaks

8-14 hours of screen time with no distance-focusing breaks accelerates ciliary muscle atrophy (Mechanism 4) and presbyopia progression. This is the most controllable factor on this list and the one most people ignore completely.

3. Chronic Sleep Deprivation

Sleep is when the retina clears metabolic waste and regenerates visual pigments. Chronic sleep debt impairs both processes. Intraocular pressure regulation is sleep-dependent. The underground consistently reports that vision protocol results are significantly better in people sleeping 7+ hours versus those under 6.

4. Cumulative UV Exposure Without Protection

UV-A and UV-B accelerate oxidative damage to both the lens (photooxidation of crystallins) and the retina (ROS production in the macula). Quality UV-blocking sunglasses are not optional — they are protective equipment for the most metabolically active tissue in your body. Not all sunglasses block UV adequately despite labels.

5. Chronic Inflammation (Systemic)

Systemic inflammation from poor diet, chronic stress, gut dysbiosis, or autoimmune conditions drives neuroinflammation that reaches the retina via the blood-retinal barrier. AMD has a significant inflammatory component. Managing systemic inflammation is vision-protective even if it’s not labeled as an “eye supplement.”

6. Smoking

Accelerates all four mechanisms simultaneously: increases oxidative stress, impairs mitochondrial function, accelerates glycation, and reduces retinal blood flow. The epidemiological data on smoking and AMD/cataracts is unambiguous. If you’re running a vision protocol while smoking, the math doesn’t work.

7. Unmanaged Screen Blue Light (Moderate Impact)

Blue light gets more media attention than it deserves relative to the other factors on this list. It’s real — 415-455nm blue light increases ROS production in retinal tissue — but it’s a moderate accelerant, not the primary driver. Quality blue-light filtering on screens and glasses helps. It’s not the game-changer the marketing suggests.

INTERESTING PERSPECTIVES

The frontier of vision optimization extends beyond standard supplements and peptides. Here are unconventional angles and emerging connections from the biohacking underground and adjacent research fields.

  • Systemic Mitochondrial Health as Ocular Insurance: The principle that retinal health is inseparable from whole-body mitochondrial function is gaining traction. Biohackers running comprehensive mitochondrial support stacks for recovery often report unexpected improvements in visual acuity and contrast sensitivity, suggesting that optimizing systemic energy production has a spillover benefit to the retina’s high-demand cells.
  • The EMF-Ocular Stress Hypothesis: A contrarian take explores whether chronic exposure to electromagnetic fields (EMF) from devices could contribute to low-grade ocular inflammation or disrupt cellular repair processes in the eye. While direct evidence is sparse, some protocols now pair vision optimization with aggressive EMF mitigation strategies, treating it as a potential environmental accelerant of oxidative stress.
  • Exosomes as a Delivery Vehicle for Retinal Repair: Beyond the horizon treatments mentioned, the most promising delivery mechanism for lens-clearing or neuroprotective compounds may be exosomes. Exosome therapy research shows these vesicles can cross biological barriers and deliver cargo directly to cells. The future of topical eye drops for serious conditions may involve exosomes loaded with therapeutic peptides or mRNA.
  • Metabolic Priming with Compounds like C60: An emerging perspective looks at using foundational antioxidants that protect mitochondrial membranes systemically, like C60 Fullerene, as a “priming” agent before running targeted ocular peptides. The theory is that reducing baseline systemic oxidative load allows compounds like SS-31 or Epitalon to work more efficiently on the specific ocular tissue.
  • Vision as a Biomarker for Systemic Aging: In advanced biohacking circles, the rate of presbyopia progression or changes in contrast sensitivity are being tracked as real-time, non-invasive biomarkers for systemic aging velocity, particularly related to glycation and mitochondrial health. A rapid decline in near vision may signal a need to intensify systemic anti-glycation protocols.

HORIZON TREATMENTS — WHAT’S COMING

These are compounds and technologies currently in development or early-stage research that may enter the underground toolkit within the next 2-5 years.

Oxysterol-Based Lens Clearing (Lanosterol/25-Hydroxycholesterol): Eye drops that dissolve lens protein aggregates. The 2015 lanosterol research generated massive excitement — the idea that cataracts could be reversed with eye drops instead of surgery. Subsequent research has been mixed, but the mechanism is real. Oxysterols reduce crystallin aggregation in vitro and in animal models. The delivery challenge (getting sufficient concentration through the cornea to the lens) remains the bottleneck. Watch this space — if the delivery problem is solved, this becomes the most significant advance in lens health in decades.

Gene Therapy for Inherited Retinal Diseases: Luxturna (voretigene neparvovec) is already FDA-approved for RPE65-mediated retinal dystrophy. The pipeline is expanding to more genetic targets. While these are disease-specific rather than optimization tools, the delivery technology (AAV vectors to the subretinal space) is potentially applicable to enhancement — delivering genes that upregulate protective enzymes or growth factors in retinal tissue.

Stem Cell-Derived RPE Transplantation: Multiple trials are underway transplanting lab-grown retinal pigment epithelium cells into patients with advanced AMD. Early results show integration and modest visual improvement. The optimization implication: if RPE cells can be transplanted, the concept of replacing aged RPE with young RPE becomes a vision-maintenance strategy rather than just a disease treatment.

Neuroprotective Eye Drops (BDNF, CNTF): Topical delivery of neurotrophic factors to protect retinal ganglion cells. Currently in clinical trials for glaucoma. The BTN framework recognizes the potential: if BDNF can be delivered effectively to the retina, the same neuroplasticity support driving the Nootropics protocol extends to retinal neurons.

CITATIONS & REFERENCES

  1. Age-Related Eye Disease Study 2 Research Group. “Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.” JAMA 309.19 (2013): 2005-2015. (Establishes the foundation for carotenoid supplementation in AMD).
  2. Khavinson, V. Kh., et al. “Peptide promotes overcoming of the division limit in human somatic cell.” Bulletin of Experimental Biology and Medicine 137.5 (2004): 503-506. (Foundational research on Epitalon and telomerase activity).
  3. Szeto, Hazel H., et al. “Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury.” Journal of the American Society of Nephrology 22.6 (2011): 1041-1052. (Mechanistic paper on SS-31’s action on mitochondrial cardiolipin).
  4. Zhang, L., et al. “SS-31 peptide enables mitochondrial targeting and therapeutic efficacy for dry age-related macular degeneration.” Investigative Ophthalmology & Visual Science 60.9 (2019): 3784. (Clinical trial data for SS-31 in AMD).
  5. Sikiric, P., et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva).” Current Pharmaceutical Design 19.1 (2013): 76-83. (Review of BPC-157’s broad tissue repair mechanisms).
  6. Pickart, L., and J. M. Vasquez-Soltero. “The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.” Oxidative Medicine and Cellular Longevity 2021 (2021). (Comprehensive review of GHK-Cu’s gene-activating and anti-inflammatory properties).
  7. Williams, P. A., et al. “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” Science 355.6326 (2017): 756-760. (Key study linking NAD+ depletion to retinal ganglion cell death).
  8. Lee, C., et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism 21.3 (2015): 443-454. (Discovery and metabolic role of MOTS-c).
  9. Rasmussen, M. L., et al. “The role of oxidative stress in the pathogenesis of age-related macular degeneration.” Antioxidants 9.9 (2020): 835. (Review detailing Mechanism 1: oxidative damage in AMD).
  10. Hejtmancik, J. F., and N. Shiels. “Overview of the lens.” Progress in Molecular Biology and Translational Science 134 (2015): 119-127. (Explanation of lens crystallin proteins and aggregation leading to cataracts).

CLOSING: YOUR EYES ARE BIOLOGICAL MACHINES

The conventional framing of vision decline as an inevitable consequence of aging is the same framing that says cognitive decline is inevitable, that muscle loss is inevitable, that hormone decline is inevitable. It’s the same error every time: confusing a treatable biological process with an irreversible fact of nature.

Your eyes run on chemistry. The retina is tissue. The lens is protein. The ciliary muscle is muscle. The mitochondria in your retinal cells respond to the same interventions that support mitochondria everywhere else in your body. The oxidative damage accumulating in your macula responds to the same antioxidant strategies that protect every other tissue.

The Tier 1 foundation alone — lutein, zeaxanthin, astaxanthin, DHA, vitamin A, bilberry, NAC, and daily ciliary muscle training — costs under $60/month and addresses all four mechanisms of decline. The peptide tiers add targeted interventions that mainstream ophthalmology won’t discuss for another decade.

Law 1: A day natural is a day wasted. Your eyes are no exception.

Next Edition: Better Than Natural: Longevity Field Report — July 2026

Better Than Natural is published quarterly. Science over ideology. Performance over profit.

Tony Huge holds commercial interests in Enhanced Labs and related brands. Compound rankings are editorial and not influenced by commercial relationships.

Popular Category